CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer

Conclusions:
This study revealed that concurrent irinotecan and capecitabine with IMRT significantly relieves local symptoms and exhibits promising efficacy with manageable toxicities in recurrent rectal cancer without prior pelvic irradiation. Improving the rate of R0 resections will be investigated in a future study.

Source: Radiation Oncology - February 28, 2015 Category: Cancer & Oncology Authors: Gang CaiJi ZhuJoshua PalmerYe XuWeigang HuWeilie GuSanjun CaiZhen Zhang Source Type: research